Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. ACN
2. ONON
3. IAUX
4. KKR
5. LLY
6. DAVA
7. MONC:IM
8. MONRY
9. NYXH
10. PNR

Go back to Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
AGIOS PHARM (NASDAQ: AGIO) Delayed: 33.95 --0 (-0%)
Previous Close $33.95    52 Week High $71.49 
Open $33.95    52 Week Low $33.50 
Day High $33.95    P/E N/A 
Day Low $33.95    EPS $-1.18 
Volume 254